FDA Expands Approved Use Of Pfizer's Xalkori, LXRX Soars On Sotagliflozin Update, BCYC Hits New High
(2) NEW YORK CITY (dpa-AFX) - Today's Daily Dose brings you news about Lexicon's regulatory update on Sotagliflozin in heart failure; FDA approval of Pfizer's XALKORI in a new indication; Bicycle's pipeline progress update and Organogenesis' progress in knee osteoarthritis trial. Read on. 1. Bicycle Rides High on Pipeline Progress Update Shares of Bicycle Therapeutics plc (BCYC) touched a new high on Thursday on the back of its pipeline progress update. The company's lead drug candidate BT1718 is progressing in the phase IIa portion of the Cancer Research UK sponsored phase I/IIa clinical t...
Source: finanznachrichten.de